Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-02-10

Clinical Trial Update: Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update for pembrolizumab in anaplastic thyroid cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Saad A Khan | Conditions: Anaplastic Thyroid Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-02-10